Separately, Kepler Capital Markets raised shares of DBV Technologies from a hold rating to a buy rating and set a €6.00 ($6.12) price objective on the stock in a research note on Thursday, August 4th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Hold and an average price target of $5.63.
DBV Technologies Stock Performance
NASDAQ DBVT opened at $1.38 on Tuesday. The stock has a market cap of $259.51 million, a P/E ratio of -2.51 and a beta of 1.43. The stock has a 50 day simple moving average of $1.65 and a two-hundred day simple moving average of $1.98. DBV Technologies has a fifty-two week low of $1.15 and a fifty-two week high of $3.43.
Hedge Funds Weigh In On DBV Technologies
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Institutional Support for Analog Devices Remains High
- Microsoft Shares: Is it Time to Back Up the Truck?
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.